Literature DB >> 22104548

Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study.

Takashi Kanai1, Takahiro Ishiwata, Tohru Kobayashi, Hiroki Sato, Mari Takizawa, Yoichi Kawamura, Hiroshi Tsujimoto, Keigo Nakatani, Naoko Ishibashi, Mitsunori Nishiyama, Yoshiho Hatai, Yuh Asano, Tomio Kobayashi, Seiichiro Takeshita, Shigeaki Nonoyama.   

Abstract

BACKGROUND: Markedly activated neutrophils or higher plasma levels of neutrophil elastase are involved in the poor response to intravenous immunoglobulin (IVIG) and the formation of coronary artery lesions (CAL) in patients with acute Kawasaki disease. We hypothesized that ulinastatin (UTI), by both direct and indirect suppression of neutrophils, would reduce the occurrence of CAL. METHODS AND
RESULTS: We retrospectively analyzed the clinical records of patients with Kawasaki disease between 1998 and 2009. Three hundred sixty-nine patients were treated with a combination of UTI, aspirin, and IVIG as an initial treatment (UTI group), and 1178 were treated with a conventional initial treatment, and IVIG with aspirin (control group). The baseline characteristics did not demonstrate notable differences between the two groups. The occurrence of CAL was significantly lower in the UTI group than in the control group (3% versus 7%; crude odds ratio [OR], 0.46; 95% confidence interval [CI], 0.25-0.86; P=0.01). The OR adjusted for sex, Gunma score (the predictive score for IVIG unresponsiveness), and dosage of initial IVIG (1 or 2 g/kg) was 0.32 (95% CI, 0.17-0.60; P<0.001). In addition, most CAL occurred in patients requiring additional rescue treatment and the proportion of those patients was significantly lower in the UTI group than in the control group (13% versus 22%; crude OR, 0.52; 95% CI, 0.38-0.73; P<0.001). The adjusted OR was 0.30 (95% CI, 0.20-0.44; P<0.001).
CONCLUSIONS: UTI was associated with fewer patients requiring additional rescue treatment and reduction of CAL in this retrospective study.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22104548     DOI: 10.1161/CIRCULATIONAHA.111.028423

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  24 in total

1.  Protective effect of ulinastatin in patients with non-small cell lung cancer after radiation therapy: a randomized, placebo-controlled study.

Authors:  Pengtao Bao; Weiguo Zhao; Yun Li; Yu Liu; Yi Zhou; Changting Liu
Journal:  Med Oncol       Date:  2014-12-12       Impact factor: 3.064

Review 2.  The Inter-α-Trypsin Inhibitor Family: Versatile Molecules in Biology and Pathology.

Authors:  Megan S Lord; James Melrose; Anthony J Day; John M Whitelock
Journal:  J Histochem Cytochem       Date:  2020-07-08       Impact factor: 2.479

Review 3.  Treatment Options for Resistant Kawasaki Disease.

Authors:  Linny Kimly Phuong; Nigel Curtis; Peter Gowdie; Jonathan Akikusa; David Burgner
Journal:  Paediatr Drugs       Date:  2018-02       Impact factor: 3.022

4.  Anti-Inflammatory Effect of Ulinastatin on the Association Between Inflammatory Phenotypes in Acute Type A Aortic Dissection.

Authors:  Hong Liu; Si-Chong Qian; Yong-Feng Shao; Hai-Yang Li
Journal:  J Inflamm Res       Date:  2022-06-27

5.  Urinary trypsin inhibitor reduced neointimal hyperplasia induced by systemic inflammation after balloon injury in rabbits.

Authors:  Junying Kong; Jian Zhang; Lin Li; Guihua Jiang; Xinchun Wang; Xiaojun Liu; Bo Yu
Journal:  Inflamm Res       Date:  2012-10-27       Impact factor: 4.575

6.  Ulinastatin activates haem oxygenase 1 antioxidant pathway and attenuates allergic inflammation.

Authors:  Dongmei Song; Geng Song; Yinghao Niu; Wei Song; Jiantao Wang; Lei Yu; Jianwang Yang; Xin Lv; Harry Steinberg; Shu Fang Liu; Baoshan Wang
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 7.  A narrative review of changes in microvascular permeability after burn.

Authors:  Yunfei Chi; Xiangyu Liu; Jiake Chai
Journal:  Ann Transl Med       Date:  2021-04

Review 8.  Natriuretic Peptides in Kawasaki Disease: the Myocardial Perspective.

Authors:  Nagib Dahdah; Anne Fournier
Journal:  Diagnostics (Basel)       Date:  2013-01-10

9.  Effect of dalteparin, a low-molecular-weight heparin, as adjunctive therapy in patients with Kawasaki disease: a retrospective study.

Authors:  Yasuji Inamo; Katsuya Saito; Maki Hasegawa; Rika Hayashi; Takahiro Nakamura; Osamu Abe; Teruaki Ishikawa; Yayoi Yoshino; Koji Hashimoto; Tatsuo Fuchigami
Journal:  BMC Pediatr       Date:  2014-01-30       Impact factor: 2.125

10.  Urinary Trypsin Inhibitor Ameliorates Seawater Immersion-Induced Intestinal Mucosa Injury via Antioxidation, Modulation of NF-κB Activity, and Its Related Cytokines in Rats with Open Abdominal Injury.

Authors:  Xing Jian Zhang; Ya Li Wang; Song Zhou; Xiaojun Xue; Qiang Liu; Wen Hua Zhang; Jun Zheng
Journal:  Gastroenterol Res Pract       Date:  2014-08-21       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.